Biocair International Ltd achieves AEO approval
September 8, 2015Medical Communications Biocair
We are pleased to announce that as of 8th September 2015 Biocair International Ltd is an Authorised Economic Operator (AEO). …
Sun Pharma strengthens opiates business
September 8, 2015Manufacturing and Production Australia, GSK, Sun Pharma, manufacturing and production, opiates
Sun Pharmaceutical Industries has strengthened its global opiates manufacturing business with the acquisition of two Australian manufacturing facilities from GlaxoSmithKline. …
New treatment option for ovarian cancer patients in Scotland
September 8, 2015Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer
The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …
EMA launches project to boost early patient access to drugs
September 8, 2015Research and Development EMA, European Medicines Agency, MAPPs, adaptive pathways, drug development, market access
The EMA is launching an adaptive pathway project to bring new medicinal products to market in Europe. The ADAPT SMART …
Novo Nordisk expands in Denmark
September 8, 2015Manufacturing and Production, Research and Development Denmark, Novo Nordisk, haemophilia API
Novo Nordisk has announced that the company is investing 500 million Danish kroner (about £48.8 million) in a new 19,000 …
Novo joins forces with MIT innovating drug devices
September 8, 2015Manufacturing and Production, Research and Development Novo Nordisk
Novo Nordisk has initiated a research collaboration with the Langer Laboratory at the Massachusetts Institute of Technology for what is …
Wave appoints Mehwish Abdeali as senior programme executive
September 8, 2015Medical Communications Mehwish Abdeali, wave
Mehwish Abdeali has been appointed as senior programme executive at Wave, a specialist medical education company. Mehwish joins Wave from …
ABPI ‘deeply concerned’ by slow UK drugs uptake
September 7, 2015Sales and Marketing ABPI, PPRS, Pharmaceutical Price Regulation Scheme, drugs bill, market access, medicines bill
The UK pharma industry paid £209 million to underwrite the UK medicines bill in second quarter of 2015, according to …
NICE recommends Keytruda for advanced skin cancer
September 7, 2015Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer
NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS. …
Pharma industry to deliver strong growth – despite price pressure
September 7, 2015Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry
The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …
Neurology comes to the fore
September 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology
Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
Celgene threatens to scale back UK clinical trial investment after CDF snub
September 4, 2015Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs
One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
Pfizer completes $15 billion Hospira acquisition
September 4, 2015Biosimilar Drugs, Hospira, Pfizer, mergers and acquisitions
Pfizer has completed its acquisition of Illinois-based injectable drugs and infusion device specialist Hospira for around $15 billion.The deal, first announced …
Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Companies braced for new round of cancer cuts
September 4, 2015Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts
Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
Novartis blood cancer drug Farydak receives EU approval
September 4, 2015Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat
The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Health ministers vow NHS tech revolution
September 3, 2015Medical Communications Jeremy Hunt, NHS, data protection, digital technology, george freeman
UK health ministers have challenged the NHS to fully utilise technology, to empower patients to manage their own healthcare needs.Their …
How ‘deep reading’ of the scientific literature will benefit pharma
September 3, 2015Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology
The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
